The inverse relationship between reduced folate carrier function and pemetrexed activity in a human colon cancer cell line

Molecular Cancer Therapeutics

Volumn 5, Issue 2, 2006, Pages 438-449

  Chattopadhyay, Shrikanta ^a   Zhao, Rongbao ^a   Krupenko, Sergery A ^b   Krupenko, Natalia ^b   Goldman, I David ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARGININE; FOLIC ACID; FOLINIC ACID; GLYCINE; METESIND GLUCURONATE; METHOTREXATE; NALPHA (4 AMINO 4 DEOXYPTEROYL) NDELTA HEMIPHTHALOYLORNITHINE; PEMETREXED; PHOSPHORIBOSYLGLYCINAMIDE FORMYLTRANSFERASE; PT 632; RALTITREXED; REDUCED FOLATE CARRIER; THYMIDYLATE SYNTHASE; TRIMETREXATE;

AMINO ACID SUBSTITUTION; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CANCER RESISTANCE; CELL LEVEL; CLONE; COLON CANCER; CONTROLLED STUDY; DRUG SENSITIVITY; DRUG TARGETING; DRUG UPTAKE; ENZYME BINDING; ENZYME INHIBITION; GENE INACTIVATION; GENE MUTATION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; ISOTOPE LABELING; MUTAGENESIS; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN FUNCTION; STRAIN DIFFERENCE; WILD TYPE;

AMINO ACID SUBSTITUTION; ANTINEOPLASTIC AGENTS; ARGININE; CARRIER PROTEINS; CELL LINE, TUMOR; COLONIC NEOPLASMS; DRUG RESISTANCE, NEOPLASM; FOLIC ACID ANTAGONISTS; GLUTAMATES; GLYCINE; GUANINE; HUMANS; LEUCOVORIN; METHOTREXATE; MUTATION; PHOSPHORIBOSYLGLYCINAMIDE FORMYLTRANSFERASE; PURINES; PYRIMIDINES; QUINAZOLINES; RECEPTORS, CELL SURFACE; THIOPHENES; THYMIDYLATE SYNTHASE;

EID: 33644975527     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-05-0243     Document Type: Article

References (38)

1. Vogelzang NJ, Rusthoven JJ, Symanowski J, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 2003;21: 2636-44.
2. Hanna N, Shepherd FA, Fossella FV, et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 2004;22:1589-97.
3. Hazarika M, White RM, Jr., Booth BP, et al. Pemetrexed in malignant pleural mesothelioma. Clin Cancer Res 2005;11:982-92.
4. Cohen MH, Johnson JR, Wang YC, Sridhara R, Pazdur R. FDA drug approval summary: pemetrexed for injection (Alimta®) for the treatment of non-small cell lung cancer. Oncologist 2005;10:363-8.
5. Zhao R, Goldman ID. Resistance to antifolates. Oncogene 2003;22: 7431-57.
6. Matherly LH, Barlowe CK, Phillips VM, Goldman ID. The effects of 4-aminoantifolates on 5-formyltetrahydrofolate metabolism in L1210 cells. J Biol Chem 1987;262:710-7.
7. Habeck LL, Mendelsohn LG, Shih C, et al. Substrate specificity of mammalian folylpolyglutamate synthetase for 5,10-dideazatetrahydrofolate analogs. Mol Pharmacol 1995;48:326-33.
8. Zhao R, Babani S, Gao F, Liu L, Goldman ID. The mechanism of transport of the multitargeted antifolate, MTA-LY231514, and its cross resistance pattern in cell with impaired transport of methotrexate. Clin Cancer Res 2000;6:3687-95.
9. Shih C, Chen VJ, Gossett LS, et al. LY231514, a pyrrolo[2,3-d]pyrimidine-based antifolate that inhibits multiple folate-requiring enzymes. Cancer Res 1997;57:1116-23.
10. Taylor EC, Kuhnt D, Shih C, et al. A dideazatetrahydrofolate analogue lacking a chiral center at C-6, N-[4-[2-(2-amino-3,4-dihydro-4-oxo-7H-pyrrolo[2, 3-d]pyrimidin-5-yl)ethyl]benzoyl]-L-glutamic acid, is an inhibitor of thymidylate synthase. J Med Chem 1992;35:4450-4.
11. Westerhof GR, Schornagel JH, Kathmann I, et al. Carrier- and receptor-mediated transport of folate antagonists targeting folate-dependent enzymes: correlates of molecular-structure and biological activity. Mol Pharmacol 1995;48:459-71.
12. Wang Y, Zhao R, Goldman ID. Characterization of a facilitative transport mechanism in HeLa cells with a low pH optimum and high affinity for pemetrexed; discrimination from transport mediated by the reduced folate carrier at low pH. Clin Cancer Res 2004;10:6256-64.
13. Chattopadhyay S, Wang Y, Zhao R, Goldman ID. Lack of impact of the loss of constitutive folate receptor α expression, achieved by RNA interference, on the activity of the new generation antifolate pemetrexed in HeLa cells. Clin Cancer Res 2004;10:7986-93.
14. Zhao R, Hanscom M, Chattopadhyay S, Goldman ID. Selective preservation of pemetrexed pharmacological activity in HeLa cells lacking the reduced folate carrier; association with the presence of a secondary transport pathway. Cancer Res 2004;64:3313-9.
15. Zhao R, Gao F, Hanscom M, Goldman ID. A prominent low-pH methotrexate transport activity in human solid tumor cells: contribution to the preservation of methotrexate pharmacological activity in HeLa cells lacking the reduced folate carrier. Clin Cancer Res 2004;10:718-27.
16. Wright JE, Vaidya CM, Chen Y, Rosowsky A. Efficient utilization of the reduced folate carrier in CCRF-CEM human leukemic lymphoblasts by the potent antifolate N(α)-(4-amino-4-deoxypteroyl)-N(δ)-hemiphthaloyl-L-ornithine (PT523) and its B-ring analogues. Biochem Pharmacol 2000;60:41-6.
17. Wang Y, Rajgopal A, Goldman ID, Zhao R. Preservation of folate transport activity with a low-pH optimum in rat IEC-6 intestinal epithelial cell lines that lack reduced folate carrier function. Am J Physiol Cell Physiol 2005;288:C65-71.
18. Skehan P, Storeng R, Scudiero D, et al. New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst 1990;82:1107-12.
19. Sharif KA, Goldman ID. Rapid determination of membrane transport parameters in adherent cells. Biotechniques 2000;28:926-8.
20. Schmitz JC, Grindey GB, Schultz RM, Priest DG. Impact of dietary folic acid on reduced folates in mouse plasma and tissues. Relationship to dideazatetrahydrofolate sensitivity. Biochem Pharmacol 1994;48: 319-25.
21. Zhao R, Gao F, Goldman ID. Marked suppression of the activity of some, but not all, antifolate compounds by augmentation of folate cofactor pools within tumor cells. Biochem Pharmacol 2001;61:857-65.
22. Zhao R, Sharina IG, Goldman ID. Pattern of mutations that results in loss of reduced folate carrier function under antifolate selective pressure augmented by chemical mutagenesis. Mol Pharmacol 1999;56:68-76.
23. Zhao R, Zhang S, Hanscom M, Chattopadhyay S, Goldman ID. Loss of reduced folate carrier function and folate depletion result in enhanced pemetrexed inhibition of purine synthesis. Clin Cancer Res 2005;11: 1294-301.
24. Andreassi JL, Moran RG. Mouse folylpoly-γ-glutamate synthetase isoforms respond differently to feedback inhibition by folylpolyglutamate cofactors. Biochemistry 2002;41:226-35.
25. Appling DR. Compartmentation of folate-mediated one-carbon metabolism in eukaryotes. FASEB J 1991;5:2645-51.
26. Matherly LH, Czajkowski CA, Muench SP, Psiakis JT. Role for cytosolic folate-binding proteins in the compartmentation of endogenous tetrahydrofolates and the 5-formyl tetrahydrofolate-mediated enhancement of 5-fluoro-2′-deoxyuridine antitumor activity in vitro. Cancer Res 1990;50:3262-9.
27. Trent DF, Seither RL, Goldman ID. Compartmentation of intracellular folates. Failure to interconvert tetrahydrofolate cofactors to dihydrofolate in mitochondria of L1210 leukemia cells treated with trimetrexate. Biochem Pharmacol 1991;42:1015-9.
28. Cook RJ, Blair JA. The distribution and chemical nature of radioactive folates in rat liver cells and rat liver mitochondria. Biochem J 1979;178: 651-9.
29. Nijhout HF, Reed MC, Budu P, Ulrich CM. A mathematical model of the folate cycle: new insights into folate homeostasis. J Biol Chem 2004;279:55008-16.
30. Seither RL, Trent DF, Mikullecky DC, Rape TJ, Goldman ID. Folate-pool interconversions and inhibition of biosynthetic processes after exposure of L1210 leukemia cells to antifolates. J Biol Chem 1989;264: 17016-23.
31. Allegra CJ, Fine RL, Drake JC, Chabner BA. The effect of methotrexate on intracellular folate pools in human MCF-7 breast cancer cells. Evidence for direct inhibition of purine synthesis. J Biol Chem 1986;261:6478-85.
32. Zhao R, Chattopadhyay S, Hanscom M, Goldman ID. Antifolate resistance in a HeLa cell line associated with impaired transport independent of the reduced folate carrier. Clin Cancer Res 2005;10: 8735-42.
33. Rhee MS, Coward JK, Galivan J. Depletion of 5,10-methylenetetrahydrofolate and 10-formyltetrahydrofolate by methotrexate in cultured hepatoma cells. Mol Pharmacol 1992;42:909-16.
34. Pizzorno G, Moroson BA, Cashmore AR, et al. Multifactorial resistance to 5,10-dideazatetrahydrofolic acid in cell lines derived from human lymphoblastic leukemia CCRF-CEM. Cancer Res 1995;55: 566-73.
35. Bunni M, Doig MT, Donato H, Kesavan V, Priest DG. Role of methylenetetrahydrofolate depletion in methotrexate-mediated intracellular thymidylate synthesis inhibition in cultured L1210 cells. Cancer Res 1988;48:3398-404.
36. Dayan A, Bertrand R, Beauchemin M, et al. Cloning and characterization of the human 5,10-methenyltetrahydrofolate synthetase-encoding cDNA. Gene 1995;165:307-11.
37. Boarman DM, Allegra CJ. Intracellular metabolism of 5-formyl tetrahydrofolate in human breast and colon cell lines. Cancer Res 1992;52:36-44.
38. Girgis S, Suh JR, Jolivet J, Stover PJ. 5-Formyltetrahydrofolate regulates homocysteine remethylation in human neuroblastoma. J Biol Chem 1997;272:4729-34.